Quantcast
Last updated on April 19, 2014 at 7:50 EDT

Latest Fibrin Stories

2011-01-27 12:47:00

ROCKVILLE, Md., Jan. 27, 2011 /PRNewswire/ -- In a study conducted jointly by the US Army Institute of Surgical Research and STB Lifesaving Technologies®, and just published in The Journal of Trauma, STB®'s FAST® (Fibrin Adhesive STat) Dressing was shown to be superior to the most effective available agents for controlling severe arterial bleeding. The study compared currently available agents with the FAST® dressing,...

2010-11-18 17:43:00

SOMERVILLE, N.J., Nov. 18, 2010 /PRNewswire/ -- Ethicon, Inc., a worldwide leader in surgical care, announced today that the company has submitted a Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the Fibrin Pad, a novel product candidate that combines Ethicon's biomaterials and plasma-derived biologics (Human Fibrinogen and Human Thrombin), to aid in stopping soft tissue bleeding during surgery. "Excessive bleeding during surgical procedures is a...

2010-11-03 09:58:00

ROCKVILLE, Md., Nov. 3, 2010 /PRNewswire/ -- STB Lifesaving Technologies® today announced that it has been awarded a Qualifying Therapeutic Discovery Project (QTDP) grant from the U.S. government in the amount of $244,479. The Qualifying Therapeutic Discovery Project was included in the Health Care Reform Bill to foster medical, life science, and biological innovation in the U.S., and the grant was based upon research expenditures for its lead product, the Fibrin...

2010-10-18 09:54:00

ROCKVILLE, Md., Oct. 18 /PRNewswire/ -- STB Lifesaving Technologies® today announced that is has completed a successful pre-Investigational New Drug (pre-IND) submission to the U.S. Food and Drug Administration (FDA) for its lead product, the Fibrin Adhesive STat®, or (FAST®) dressing. STB® has conducted successful animal studies for the FAST® dressing with both military and commercial partners and...

2010-07-07 11:33:00

ROCKVILLE, Md., July 7 /PRNewswire/ -- For the third consecutive year the Department of Defense demonstrated its commitment to help save the lives of our troops by providing STB Lifesaving Technologies® with $2.85 million of funding. The award is to further advance the development of STB®'s Fibrin Adhesive STat (FAST®) dressing, designed to be effective against the full spectrum of blood loss, including severe arterial and venous...

2010-06-20 08:43:26

Research harnesses enzyme's anti-blood clotting abilities In research led by a Saint Louis University investigator, molecular biologists have discovered a way to harness the enzyme thrombin's anti-blood clotting properties. The finding opens the door to new medications that will treat diseases related to thrombosis, the presence of blood clots in blood vessels, which is responsible for nearly a third of all deaths in the U.S. "Thrombosis is one of the most prevalent causes of fatal disease,"...

2010-06-17 00:58:00

LEIDEN, The Netherlands and SEATTLE, June 17, 2010 /PRNewswire/ -- ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced that it has entered into an agreement with CSL Behring for the clinical and commercial supply of plasma-based fibrinogen and thrombin, for the manufacturing of Fibrocaps(TM). CSL Behring is a leader in the plasma protein therapeutics industry and a subsidiary of CSL Limited (ASX: CSL), a global...

2010-06-09 21:39:05

New research suggests that abnormalities in the process of blood clot formation may contribute to the pathogenesis of Alzheimer's disease (AD). The study, published by Cell Press in the June 10 issue of the journal Neuron, advances our understanding of the link between vascular pathology and AD and proposes a new therapeutic strategy aimed at slowing cognitive decline. One documented characteristic of AD is the deposition of ?-amyloid peptide (A?) in the walls of cerebral blood vessels, known...

0dec7530bda0399717e4bc81f31be9e51
2010-05-19 08:15:00

Fibrin, the primary ingredient of blood clots, creates a fibrous network that stems the loss of blood at an injury site. But beyond this essential work, fibrin can also cause heart attack, stroke and tissue damage by forming clots that block blood vessels. Fibrin forms when an enzyme removes parts of a blood protein called fibrinogen, exposing "knobs" that fit into "holes" located on both ends of fibrinogen molecules. Uncovering these knobs allows the fibrinogen molecules to attach to one...

2010-05-10 09:01:10

A joint clinical trial conducted by the University Hospital and the University of Gothenburg, Sweden, found that an element in human blood, fibrinogen, is likely more vital to the blood's clotting ability in connection with heart surgery than previously considered. If the patients also receive a dose of fibrinogen prior to the procedure, this reduces the risk of hemorrhage during and after surgery. These results may open the door to new strategies in reducing bleeding complications in cardiac...